These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 33799592)

  • 21. The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells.
    Klymenko T; Brandenburg M; Morrow C; Dive C; Makin G
    Mol Cancer Ther; 2011 Dec; 10(12):2373-83. PubMed ID: 22006676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
    Sasaki N; Kuroda J; Nagoshi H; Yamamoto M; Kobayashi S; Tsutsumi Y; Kobayashi T; Shimura Y; Matsumoto Y; Taki T; Nishida K; Horiike S; Akao Y; Taniwaki M
    Exp Hematol; 2011 Aug; 39(8):817-28.e1. PubMed ID: 21640157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
    Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.
    Vandenberg CJ; Cory S
    Blood; 2013 Mar; 121(12):2285-8. PubMed ID: 23341542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
    Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BH3 mimetics: status of the field and new developments.
    Billard C
    Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A BH3 Mimetic for Killing Cancer Cells.
    Green DR
    Cell; 2016 Jun; 165(7):1560. PubMed ID: 27315468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement.
    Liu L; Mo W; Chen M; Qu Y; Wang P; Liang Y; Yan X
    BMC Cancer; 2024 Jun; 24(1):761. PubMed ID: 38918775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
    Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
    Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
    Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
    Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
    Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics.
    Knight T; Luedtke D; Edwards H; Taub JW; Ge Y
    Biochem Pharmacol; 2019 Apr; 162():250-261. PubMed ID: 30668936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The BCL-2 arbiters of apoptosis and their growing role as cancer targets.
    Adams JM; Cory S
    Cell Death Differ; 2018 Jan; 25(1):27-36. PubMed ID: 29099483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
    Oltersdorf T; Elmore SW; Shoemaker AR; Armstrong RC; Augeri DJ; Belli BA; Bruncko M; Deckwerth TL; Dinges J; Hajduk PJ; Joseph MK; Kitada S; Korsmeyer SJ; Kunzer AR; Letai A; Li C; Mitten MJ; Nettesheim DG; Ng S; Nimmer PM; O'Connor JM; Oleksijew A; Petros AM; Reed JC; Shen W; Tahir SK; Thompson CB; Tomaselli KJ; Wang B; Wendt MD; Zhang H; Fesik SW; Rosenberg SH
    Nature; 2005 Jun; 435(7042):677-81. PubMed ID: 15902208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subversion of the Bcl-2 life/death switch in cancer development and therapy.
    Adams JM; Huang DC; Strasser A; Willis S; Chen L; Wei A; van Delft M; Fletcher JI; Puthalakath H; Kuroda J; Michalak EM; Kelly PN; Bouillet P; Villunger A; O'Reilly L; Bath ML; Smith DP; Egle A; Harris AW; Hinds M; Colman P; Cory S
    Cold Spring Harb Symp Quant Biol; 2005; 70():469-77. PubMed ID: 16869785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Bcl-2 Family Proteins: What, Where, When?
    Senichkin VV; Pervushin NV; Zuev AP; Zhivotovsky B; Kopeina GS
    Biochemistry (Mosc); 2020 Oct; 85(10):1210-1226. PubMed ID: 33202206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies.
    Delbridge AR; Grabow S; Strasser A; Vaux DL
    Nat Rev Cancer; 2016 Feb; 16(2):99-109. PubMed ID: 26822577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting BCL2 for the treatment of lymphoid malignancies.
    Anderson MA; Huang D; Roberts A
    Semin Hematol; 2014 Jul; 51(3):219-27. PubMed ID: 25048785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.